Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

A global phase 2 study, AKITA, was initiated in 2022. Learn more about the clinical development of RMC-035.

Read more

CLINICAL STUDIES

RMC-035, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

RMC-035

Acute kidney injury is a large market. 13 million people gloabally are affected every year.

Read more

INVESTOR RELATIONS

Press releases
  • 09 Jan 2023  ·  Regulatory information

    Guard Therapeutics receives patent approval for RMC-035 in China

    Read more
  • 20 Dec 2022  ·  Regulatory information

    Guard Therapeutics presents the Nomination Committee for 2023

    Read more
  • 10 Nov 2022  ·  Regulatory information

    Guard Therapeutics has decided to carry out a directed share issue of SEK 120 million, partly subject to subsequent approval by an extraordinary general meeting

    Read more
  • 10 Nov 2022  ·  Regulatory information

    Guard Therapeutics explores the conditions to carry out a directed share issue of approximately SEK 115 million

    Read more
Show more
Calendar & reports
  • 22 Feb 2023

    Year-end report 2022

    Read more
  • 09 May 2023

    Annual General Meeting 2023 (including Annual Report 2022)

    Read more
  • 09 May 2023

    Interim report January-March 2023

    Read more
  • 24 Aug 2023

    Interim report April-June 2023

    Read more
Reports, presentations & in media
  • 09 Nov 2022 / Presentation

    CEO interview following Fast Track designation (November 09, 2022)

    Read more
  • 21 Sep 2022 / Presentation

    Guard Therapeutics Capital Markets Day

    Read more
  • 13 Sep 2022 / Presentation

    ABGSC -Investor Day Seminar

    Read more
  • 18 May 2022 / Presentation

    ABGSC Life Science Summit (Stockholm, Sweden)

    Read more
Show more